Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLD200
- Development stage
- Phase 3
- Lead developer
- Ironshore
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
HLD200 is a proprietary, once-daily, oral, evening-dosed delayed-release and extended-release (DR/ER) formulation of methylphenidate. It is designed to provide a controlled delay in drug release (6–10 hours after dosing), followed by an extended absorption profile that delivers therapeutic levels of methylphenidate upon awakening and throughout the day. The formulation uses the DELEXIS drug delivery platform to achieve this pharmacokinetic profile. HLD200 is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older and has been studied in adults as well. Its unique evening dosing aims to address early morning ADHD symptoms without requiring pre-awakening administration[1][2][4][5][9].
- Brand names
- Jornay PMBenjorna
- Other names
- methylphenidate delayed releasemethylphenidate hydrochloride extended release
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)MAOA (Monoamine oxidase A)
Beyond the preview
Go deeper on HLD200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLD200.